文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

经导管三尖瓣置换的早期单部位经验。

Early Single-Site Experience With Transcatheter Tricuspid Valve Replacement.

机构信息

Columbia University Medical Center/NewYork Presbyterian Hospital, New York, New York.

Columbia University Medical Center/NewYork Presbyterian Hospital, New York, New York.

出版信息

JACC Cardiovasc Imaging. 2019 Mar;12(3):416-429. doi: 10.1016/j.jcmg.2018.08.034. Epub 2018 Dec 12.


DOI:10.1016/j.jcmg.2018.08.034
PMID:30553658
Abstract

OBJECTIVES: This study presents a single-site experience of 5 patients with severe tricuspid regurgitation (TR) who underwent implantation of a novel transcatheter tricuspid valve replacement device. BACKGROUND: Functional TR is the most common etiology of severe TR in the developed world and is associated with unfavorable clinical outcomes. Although numerous transcatheter repair devices are currently in early clinical trials, most result in incomplete degrees of TR reduction and functional improvement. METHODS: Transcatheter tricuspid valve replacement was performed in 5 patients with compassionate use of the novel GATE System. All patients had symptomatic, massive and/or torrential TR at baseline. All patients had computed tomography, transthoracic and transesophageal echocardiographic assessment of the tricuspid valve and right heart anatomy. All patients had a surgical transatrial approach performed with valve implantation guided by fluoroscopy and intraprocedural transesophageal echocardiography. RESULTS: Baseline characteristics of the patients showed a substantial burden of comorbidities. All patients had successful implantation of the transcatheter valve, with significant reduction of TR to ≤2+. Baseline poor right ventricular (RV) function measured by global longitudinal strain and RV change in pressure divided by change in time were associated with post-implantation RV failure and poor clinical outcomes in this small group. Four of the 5 patients were followed for 3 to 6 months following the initial implantation and showed evidence of RV remodeling, increased cardiac output, and reduction in New York Heart Association functional class. CONCLUSIONS: Implantation of a first-generation TTVR device was technically feasible in patients with more than severe TR. Transcatheter tricuspid valve replacement was associated with RV remodeling, increased cardiac output, and improvement in New York Heart Association functional class in most patients. Further studies are needed to refine patient population selection for this device and to determine long-term outcomes.

摘要

目的:本研究报告了 5 例严重三尖瓣反流(TR)患者在单一中心接受新型经导管三尖瓣置换装置植入的经验。

背景:功能性 TR 是发达国家最常见的严重 TR 病因,与不良临床结局相关。尽管目前有许多经导管修复装置处于早期临床试验阶段,但大多数装置只能部分减轻 TR 程度并改善功能。

方法:5 例患者因同情使用新型 GATE 系统而接受经导管三尖瓣置换术。所有患者在基线时均有症状性、大量和/或 torrential TR。所有患者均进行了计算机断层扫描、经胸超声心动图和经食管超声心动图评估三尖瓣和右心解剖结构。所有患者均采用经心房入路进行手术,并在透视和术中经食管超声心动图的引导下植入瓣膜。

结果:患者的基线特征显示出大量合并症的负担。所有患者均成功植入了经导管瓣膜,TR 显著降低至≤2+。通过整体纵向应变和 RV 压力变化除以时间变化来衡量的基线较差的右心室(RV)功能与植入后 RV 衰竭和该小群体不良临床结局相关。5 例患者中的 4 例在初始植入后随访 3 至 6 个月,显示 RV 重塑、心输出量增加和纽约心脏协会功能分级降低的证据。

结论:在存在严重以上 TR 的患者中,植入第一代 TTVR 装置在技术上是可行的。在大多数患者中,经导管三尖瓣置换术与 RV 重塑、心输出量增加和纽约心脏协会功能分级改善相关。需要进一步的研究来细化该装置的患者人群选择,并确定长期结果。

相似文献

[1]
Early Single-Site Experience With Transcatheter Tricuspid Valve Replacement.

JACC Cardiovasc Imaging. 2018-12-12

[2]
Transcatheter Tricuspid Valve Repair With a New Transcatheter Coaptation System for the Treatment of Severe Tricuspid Regurgitation: 1-Year Clinical and Echocardiographic Results.

JACC Cardiovasc Interv. 2017-8-2

[3]
Long-Term Outcomes of the FORMA Transcatheter Tricuspid Valve Repair System for the Treatment of Severe Tricuspid Regurgitation: Insights From the First-in-Human Experience.

JACC Cardiovasc Interv. 2019-8-12

[4]
Compassionate Use of the PASCAL Transcatheter Valve Repair System for Severe Tricuspid Regurgitation: A Multicenter, Observational, First-in-Human Experience.

JACC Cardiovasc Interv. 2019-12-23

[5]
Interventional Treatment of Severe Tricuspid Regurgitation: Early Clinical Experience in a Multicenter, Observational, First-in-Man Study.

Circ Cardiovasc Interv. 2018-2

[6]
The International Multicenter TriValve Registry: Which Patients Are Undergoing Transcatheter Tricuspid Repair?

JACC Cardiovasc Interv. 2017-10-9

[7]
Transcatheter Valve-in-Ring Implantation for the Treatment of Residual or Recurrent Tricuspid Valve Dysfunction After Prior Surgical Repair.

JACC Cardiovasc Interv. 2017-1-9

[8]
Physiological and Clinical Consequences of Right Ventricular Volume Overload Reduction After Transcatheter Treatment for Tricuspid Regurgitation.

JACC Cardiovasc Interv. 2019-7-17

[9]
Predictors of Procedural and Clinical Outcomes in Patients With Symptomatic Tricuspid Regurgitation Undergoing Transcatheter Edge-to-Edge Repair.

JACC Cardiovasc Interv. 2018-6-25

[10]
1-Year Outcomes After Edge-to-Edge Valve Repair for Symptomatic Tricuspid Regurgitation: Results From the TriValve Registry.

JACC Cardiovasc Interv. 2019-8-12

引用本文的文献

[1]
Percutaneous interventions in tricuspid valve disease: a new era in cardiac treatment.

Ann Med Surg (Lond). 2025-5-30

[2]
Short-term prognosis of patients in different stages of severe tricuspid regurgitation after transcatheter tricuspid-valve replacement.

Quant Imaging Med Surg. 2025-8-1

[3]
Echocardiographic Imaging to Guide Tricuspid Interventions.

Struct Heart. 2025-5-30

[4]
Efficacy and Safety of Transcatheter Tricuspid Valve Replacement in Patients With Moderate to Severe Tricuspid Regurgitation: A Systematic Review and Meta-Analysis on Clinical Outcomes and Echocardiographic Indices.

Health Sci Rep. 2025-6-23

[5]
Management of patients with transvalvular right ventricular leads undergoing transcatheter tricuspid valve interventions: a scientific statement of the European Heart Rhythm Association and the European Association of Percutaneous Cardiovascular Interventions of the ESC endorsed by the Heart Rhythm Society, the Asian Pacific Heart Rhythm Society and the Canadian Heart Rhythm Society.

Europace. 2025-5-7

[6]
Clinical Impact of Renal Dysfunction in Patients with Severe Tricuspid Regurgitation and Chronic Heart Failure.

Rev Cardiovasc Med. 2025-3-5

[7]
Transcatheter Tricuspid Valve Intervention: Current Perspective.

US Cardiol. 2021-6-30

[8]
Rediscovered and Unforgotten: Transcatheter Interventions for the Treatment of Severe Tricuspid Valve Regurgitation.

US Cardiol. 2021-11-2

[9]
Safety and Efficacy of Pivot-Balloon for Severe Tricuspid Regurgitation: The First-in-Man Experiences.

Korean Circ J. 2025-1

[10]
Transcatheter Tricuspid Valve Replacement: Case Selection, Technical Considerations, and Procedural Planning.

US Cardiol. 2023-8-17

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索